Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · IEX Real-Time Price · USD

2.94

-0.21 (-6.67%)

At close: Sep 28, 2023, 4:00 PM

2.75

-0.19 (-6.46%)

Pre-market: Sep 29, 2023, 7:09 AM EDT

Cash Flow Statement (Annual)

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015
Net Income	-157.04	-125.75	-59.46	-15.01	-8.96	-6.29	-2.97	-20.8
Depreciation & Amortization	0	0	0	0	0	0.09	0.05	0.01
Share-Based Compensation	44.19	40.49	20.78	3.17	0.52	0.7	1.21	1.98
Other Operating Activities	9.05	-6.62	10.87	-0.26	2.44	-0.97	-11.43	2.59
Operating Cash Flow	-103.8	-91.87	-27.81	-12.09	-6	-6.47	-13.14	-16.23
Capital Expenditures	0	0	0	0	-0.01	-0.05	-0.56	-0.02
Change in Investments	19.73	-54.12	-34.45	-80.16	0	0	0	0
Investing Cash Flow	19.73	-54.12	-34.45	-80.16	-0.01	-0.05	-0.56	-0.02
Share Issuance / Repurchase	43.43	185.31	20.53	122.03	0	0	0	0
Debt Issued / Paid	0	0	-0.11	-0.37	0.01	-0.27	-0.26	-0.29
Other Financing Activities	1.59	2.63	8.06	4.45	6.53	-	-	13.45
Financing Cash Flow	45.02	187.94	28.47	126.11	6.54	-0.27	-0.26	13.16
Net Cash Flow	-39.05	41.95	-33.78	33.85	0.53	-6.79	-13.97	-3.09
Free Cash Flow	-103.8	-91.87	-27.81	-12.09	-6.01	-6.52	-13.71	-16.25
Free Cash Flow Per Share	-3.50	-5.23	-1.78	-1.31	-1.92	-2.16	-4.73	-6.54

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).